Please assess the completion status of the following clinical trial:

Trial Title: A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Histologically confirmed metastatic melanoma (AJCC stage IV) or unresectable melanoma (AJCC Stage III)~* Prior failure of \>/= 1 prior treatment regimens for metastatic or unresectable melanoma due to disease progression or unacceptable toxicity and for whom no standard therapy is available~* Measurable disease according to RECIST criteria~* Adequate bone marrow, liver and renal function~* Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception through the course of the study treatment and for 6 months after the last dose of study treatment~Exclusion Criteria:~* Treatment with cytotoxic or antibody based therapy within 21 days prior to first dose of study treatment, or with any other anti-cancer therapy within 5 half-lives of the therapy prior to first dose of study treatment~* Known active infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds)~* Current Grad \>/= 2 toxicity (except alopecia or anorexia) from prior therapy~* Grade \>/= 2 peripheral neuropathy~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapies (or recombinant antibody-related fusion proteins)~* Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis~* Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)~* Evidence of significant uncontrolled concomitant disease or disorder~* Pregnant or lactating women~* Prior treatment with any other antibody-drug conjugate (ADC) compound containing monomethyl auristatin E (MMAE) for the treatment of melanoma~* Previous participation in a clinical trial within 30 days of the day of first study drug administration (Cycle 1, Day 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).